Journal Pre-proof

Dose-response Relationship between Mandibular Advancement and OSA Burden: Dissociated Effects on Supine and Non-Supine AHI

Jean-Benoît Martinot, Nhat-Nam Le-Dong, Chloé Cantero, Didier Clause, Fernanda R. Almeida, Peter A. Cistulli, Jean-Louis Pépin

PII: S1389-9457(26)00235-2

DOI: https://doi.org/10.1016/j.sleep.2026.108996

Reference: SLEEP 108996

To appear in: *Sleep Medicine*

Received Date: 7 April 2026

Revised Date: 23 April 2026

Accepted Date: 29 April 2026

Please cite this article as: Martinot J-B, Le-Dong N-N, Cantero C, Clause D, Almeida FR, Cistulli PA, Pépin J-L, Dose-response Relationship between Mandibular Advancement and OSA Burden: Dissociated Effects on Supine and Non-Supine AHI, *Sleep Medicine*, https://doi.org/10.1016/j.sleep.2026.108996.

Dose-response Relationship between Mandibular Advancement and OSA Burden: Dissociated Effects on Supine and Non-Supine AHI

Jean-Benoît Martinot[1,2], Nhat-Nam Le-Dong[3], Chloé Cantero[4], Didier Clause[1], Fernanda R. Almeida[5], Peter A. Cistulli[6,7], Jean-Louis Pépin[8,9]

[1] Sleep Laboratory, CHU-UcL, Namur Site Sainte-Elisabeth, Namur, Belgium.

[2] Institute of Experimental and Clinical Research, UcL Bruxelles Woluwe, Brussels, Belgium.

[3] Sunrise, Namur, Belgium.

[4] Division of Pulmonary Diseases, Geneva University Hospitals (HUG), Geneva, Switzerland.

[5] Division of Orthodontics and Dental Sleep Medicine, Department of Oral Health Sciences, Faculty of Dentistry, University of British Columbia, Vancouver, Canada.

[6] Charles Perkins Centre and Sydney Medical School, University of Sydney, Camperdown, Sydney, Australia.

[7] Department of Respiratory and Sleep Medicine, Royal North Shore Hospital, St Leonards, Sydney, Australia.

[8] Grenoble Alpes University, HP2 Laboratory, Inserm U1300, Grenoble, France.

[9] EFCR Laboratory, Grenoble Alpes University Hospital, Grenoble, France.

Corresponding author: Jean-Benoît Martinot.

Centre du Sommeil et de la Vigilance. CHU Université catholique de Louvain, Namur Site Sainte-Elisabeth. 15, Place Louise Godin. 5000 Namur, Belgium.

Tel: +32 495502608. Fax: +32 81570754. Email: martinot.j@respisom.be

Ethics

The study was approved by the Comité d'Ethique Hospitalo-Facultaire-Universitaire de Liège (IRB #00004890), and all participants provided written informed consent.

Author contributions

JBM and NNLD designed the study.

JBM and DC conducted the research procedure and had full access to all study data.

JBM, NNLD, PAC, AF and JLP performed data analysis and interpretation.

JBM, NNLD, CC and AF prepared the first draft of the manuscript.

DC, PAC and JLP reviewed and edited the final manuscript.

All authors made the decision to submit the manuscript for publication and assume responsibility for the accuracy and completeness of the analyses and for the fidelity of this report to the study protocol.

Acknowledgments

The authors wish to thank Ms. Mathilde Leval and Ms. Bao Truc Nguyen Ham for their assistance in data collection.

Dose-response Relationship between Mandibular Advancement and OSA Burden: Dissociated Effects on Supine and Non-Supine AHI

Abstract

Background and Objective: A key unresolved mechanistic question in obstructive sleep apnea (OSA) therapy with mandibular advancement devices (MAD) is how incremental advancement affects position-specific disease burden.

This study aimed to evaluate the dynamic changes in apnea-hypopnea index (AHI) in different body positions in response to stepwise mandibular advancements, using the mandibular jaw movement (MJM)-based monitoring technology.

Methods: A prospective cohort study was conducted in OSA patients eligible for MAD therapy with a standardized titration protocol. Home sleep tests with MJM analysis were performed at baseline, and three successive advancement levels (initial, intermediate, and maximal). Regression analysis with adjustments for time-varying confounding factors was applied to estimate the adjusted changes in residual AHI in supine and non-supine positions.

Results: Ninety-six patients completed titration and follow-up. MAD titration did not significantly modify supine sleep time. Relative to baseline, early and significant improvements were observed for both supine and non-supine AHI at the initial advancement level (relative reduction of -60.1% [95% CI: -67.9; -52.2] and -55.0% [95% CI: -61.1; -48.9], respectively). Thereafter, AHI responses diverged: supine AHI continued a progressive reduction through to end of titration (mean cumulative change: -78.4% [95% CI: -82.7; -74.2]), whereas non-supine AHI showed little additional change beyond the initial improvement (mean cumulative change: -63.3% [95% CI: -68.2; -58.3]). Positional OSA prevalence was reduced from 38.5% at baseline to 18.3% at endpoint.

Conclusions: These findings underscore the value of continuous, home-based monitoring of position-specific residual AHI during MAD titration, and support integrating MJM analysis into MAD therapy workflows.

Abstract word count: 250/250

Keywords: obstructive sleep apnea, oral appliance therapy, mandibular advancement device, positional OSA, mandibular jaw movement

Main text word count: 3545

INTRODUCTION

Mandibular advancement devices (MADs) are currently recommended as an alternative treatment for patients with obstructive sleep apnea (OSA), with clinical effectiveness comparable to positive airway pressure (PAP) therapy [1,2]. However, unlike PAP, which provides a position-independent pneumatic splint of the upper airway (UA), the stabilizing effect of MADs may be inherently posture-dependent. During supine sleep, gravitational forces promote posterior displacement of UA structures, increasing the collapsing load on the pharynx [3]. Accordingly, maintaining UA patency in the supine posture may require a greater mandibular advancement, underscoring the importance of precisely characterizing position-specific residual AHI.

Indeed, studies focusing on positional obstructive sleep apnea (POSA) report an attenuated response in patients with baseline POSA [4], with residual apnea–hypopnea events predominantly occurring during supine sleep [5]. Persistent residual POSA has been observed in a substantial proportion of treated patients [6,7], and in some cases MAD therapy may even induce a shift toward a supine-dependent phenotype [5,6].

A central unresolved mechanistic question is how incremental mandibular advancement progressively modulates position-dependent OSA burden over time, and whether this dose-response trajectory differs between supine and non-supine AHI. Because most POSA-focused studies reduce this dynamic process to a simple pre-post comparison, dose-response dynamics and posture-specific AHI response patterns remain poorly characterized. A multi-level, repeated-measures titration framework is therefore needed to address this gap.

In addition, in-laboratory testing may significantly alter patients' habitual sleep posture, increasing supine exposure due to unfamiliar environment and extensive wiring [8,9]. By contrast, unobtrusive and simplified home sleep tests (HSTs) better preserve habitual sleeping conditions, thereby providing a more accurate representation of real-life positional vulnerability [10].

Recently, a novel mandibular jaw movement (MJM)-based monitoring approach has been clinically validated as a reliable and effective solution for home-based monitoring during

MAD titration [11]. In a subsequent study, repeated at-home MJM assessments further enabled characterization of a dose-response relationship, with AHI improving as mandibular advancement levels increased [12]. Beyond its core function of capturing MJM for sleep staging and respiratory event detection [13], the MJM sensor's built-in accelerometer allows continuous real-time monitoring of sleep posture [14]. This enables posture-stratified quantification of sleep time and apnea-hypopnea burden (supine versus non-supine), making MJM-based analysis well suited for home-based monitoring of position-specific AHI reduction during MAD titration.

This study aims to determine the dynamic changes in position-specific residual AHI across stepwise mandibular advancements at home, using MJM-based monitoring.

METHODS

Study design and participants

This prospective cohort study enrolled consecutive adults with a confirmed OSA diagnosis who were eligible for MAD therapy and consented to a longitudinal follow-up program with repeated home-based measurements at successive mandibular advancement levels. Participants were recruited at the sleep laboratory of a university hospital […] between January 2021 and December 2022. The protocol was approved by the Comité d'Ethique Hospitalo-Facultaire-Universitaire […], and all participants provided written informed consent. Detailed eligibility criteria are provided in the Supplementary Methods (Section 1), and the study workflow is summarized in Figure 1.

OSA diagnosis

OSA diagnosis was confirmed using in-laboratory polysomnography (PSG) (Somnoscreen Plus, Somnomedics, Randersacker, Germany), scored by two trained technicians according to American Academy of Sleep Medicine (AASM) criteria, applying the recommended apnea and hypopnea definitions [15,16]. Final diagnosis and severity grading were determined following the International Classification of Sleep Disorders, 3rd edition (ICSD-3) [17].

MAD titration protocol

MAD therapy was offered to patients with PSG-confirmed OSA, in accordance with the AASM joint guideline on MAD therapy [1]. Patients were excluded if they had significant cardiovascular or metabolic comorbidities, severe daytime sleepiness, safety-critical driving occupations, or compromised stomatognathic conditions (fewer than eight teeth per arch, temporomandibular disorder, or periodontitis).

Treatment was performed using a two-piece, custom-made, adjustable MAD (NOA; OrthoApnea, Málaga, Spain) (further details are provided in Section 2 of the Supplemental Methodology).

For each patient, the maximal protrusion range (MPR) was determined, as the distance (in millimeters) between the mandibular positions of maximal retrusion and voluntary maximal protrusion. At initiation, the device was uniformly set at 60% of the MPR for all patients. At each titration step, patients self-assessed their clinical status through telephone interviews and digital surveys, collecting information on sleep satisfaction, residual sleepiness, snoring (as reported by the bed partner), and adverse events. Under the supervision of a sleep-specialized dentist, the MAD was advanced in 1-mm or 2-mm increments at successive steps, based on persistence or worsening of OSA symptoms and patient tolerability.

During the titration and follow-up period, MAD therapy was the only OSA-directed intervention, with no additional medications or adjunctive treatments intended to modify OSA severity.

Multiple at-home assessments of treatment response

Over the 6-month study period, each patient underwent single-night, home-based sleep testing at four time points corresponding to incremental mandibular advancement levels (Figure 1): 1) baseline, 2) initial advancement (60% of MPR), 3) intermediate advancement (+1 or +2 mm beyond the starting point), and 4) final advancement (an additional 1mm beyond the intermediate level). This design enabled the evaluation of residual, position-dependent OSA burden at each therapeutic level. Assessments were performed only after patients had reached a stable condition, defined as maintaining the target advancement level for at least 10–15 days without discomfort. Importantly, test results were not disclosed to the treating physician and were not used to guide titration. Each evaluation was conducted at home under

naturalistic sleep conditions using MJM-based monitoring (Sunrise, Namur, Belgium) to quantify position-specific clinical indices, including total sleep time (TST) proportions and residual AHI in supine and non-supine postures.

The operating mechanisms of MJM analysis are described in the Supplementary Methodology (Section 3). Briefly, MJM signals are captured using a lightweight, single-point sensor affixed to the patient's chin. The sensor's inertial measurement unit includes a gyroscope and an accelerometer, which respectively record the movement and position of the mandible across three axes. Using artificial intelligence, the system identifies specific MJM signal patterns associated with physiological or pathological events, such as sleep stages, arousals, and respiratory disturbances. Supine versus non-supine position is determined from the accelerometer signal (e-Figure 1). Combining these outputs enables position-specific estimation of TST proportions and AHI.

Data analysis

The R programming language [18] was used to perform data analysis and visualization.

Sample size: The dataset was derived from a previously published prospective study [11]. An *ad-hoc* analysis was conducted to assess whether the sample size was adequate to detect a significant dose-response relationship between incremental mandibular advancement and supine AHI, in line with the primary objective. This procedure is detailed in Section 4.2 of the Supplemental Methodology.

Main analysis: Baseline characteristics and titration data, including incremental protrusion levels, self-reported symptoms and tolerability outcomes were summarized by using descriptive statistics. Categorial variables were presented as proportions and quantitative variables as medians with interquartile range (IQR). Primary outcomes were supine and non-supine sleep time proportions, as well as supine and non-supine AHI. Positional (supine-dependent) OSA was defined as supine AHI at least twice the non-supine AHI, per the commonly used Cartwright criterion (1984) [19]. A full list of position-dependent outcomes and their definitions is provided in Section 4.1 of the Supplemental Methodology.

Average treatment effects across the four advancement levels on position-dependent outcomes were estimated using generalized linear mixed model (GLMM) regression analysis with appropriate probability distributions according to the outcome variables (zero-adjusted

Gamma for hourly indices, zero-inflated negative binomial for event counts, and beta distribution for sleep time proportions). The regression analysis also implemented a generalized inverse probability treatment weighting (IPTW) process [20-24] to adjust for the time-varying confounding (detailed in Section 4.3 of the Supplemental Methodology). As an exploratory post-hoc analysis, sex-specific conditional average marginal effects for the principal outcomes were estimated from regression models. These analyses were implemented using the gamlss [25] and marginaleffects [26] packages. Statistical inference was based on 95% confidence intervals (CIs) and two-sided Wald tests, with Benjamini-Hochberg adjustment for multiple comparisons and a significance threshold of $p<0.005$.

RESULTS

Study population characteristics

A total of 96 OSA patients were included in the final analysis (Figure 1). Baseline demographic and clinical characteristics are detailed in Table 1. Participants were predominantly middle-aged adults with excess body weight and a male predominance. At diagnosis, OSA severity was heterogeneous, with most patients exhibiting moderate to severe disease. Subjective daytime sleepiness was frequently reported. Polysomnographic evaluation revealed a moderate to severe AHI (10^{th}-90^{th} percentile range: 18.6 to 34.6 events/h), accompanied by impaired sleep continuity and intermittent oxygen desaturation.

Baseline position-dependent OSA profile

Baseline assessments conducted under natural home-sleeping conditions showed relatively limited supine position exposure, accounting for a modest proportion of TST (5^{th}–95^{th} percentile: 6.8-37.9% of TST).

Despite a lower event density (median: 17.4 events/h), the non-supine position contributed more substantially to the overall apnea-hypopnea event burden (84 vs 35.5 events). Conversely, the supine position was associated with a higher event density (median: 20.3 events/h), resulting in a disproportionate contribution to the total event burden despite shorter exposure time.

A substantial subset of patients (38.5%) met Cartwright's criteria [19] for positional OSA, consistent with a mixed phenotype characterized by a clinically relevant positional component.

Progression of mandibular advancement during titration

As summarized in e-Table 2, MAD titration followed a standardized stepwise protocol and demonstrated consistent tolerability. The MAD was applied to all patients at a uniform, conventional initial protrusion of 60% of MPR. At the intermediate step, mandibular advancement was increased to approximately 68% of MPR, with only one patient requiring treatment discontinuation. Thereafter, advancement was gradually and individually adjusted until subjective symptom resolution or attainment of a maximally comfortable position. At the final step, 93 patients achieved a median advancement of approximately 76% of MPR, corresponding to an absolute position of 9.8 mm. Across all titration levels, no clinically meaningful increase in adverse effects was observed. Patient-reported functional discomfort and oro-facial side effects remained low and stable throughout titration.

Supine sleep exposure across titration steps

Overall, MAD titration did not produce a clinically meaningful change in supine sleep exposure, defined as the proportion of TST spent in the supine position (e-Table 3, Table 2, e-Figure 4). Relative to baseline, the initial protrusion was associated with a small reduction in supine sleep proportion (-4.3 %TST; 95% CI: -7.5 to -1.2). The proportion of supine sleep then returned toward baseline at the intermediate level (median: 18.1 %TST) and remained stable at the final level (median: 17.0 %TST), corresponding to a modest cumulative change from baseline (-3.3 %TST, 95% CI: -6.5 to -0.1). After adjustment for multiple comparisons, none of these pairwise contrasts for supine sleep proportion was statistically significant.

Dose-response pattern of residual position-specific AHI

Data visualization (Figure 2) and model-based estimates (Table 2) revealed distinct trajectories of supine versus non-supine residual AHI across incremental mandibular advancement levels.

Relative to baseline, both supine and non-supine AHI improved early, substantially and to a similar extent at the initial protrusion (-60.1% [95% CI: −67.9 to −52.2] and -55.0% [95%

CI: −61.1 to −48.9], respectively). Thereafter, responses diverged. Supine AHI showed additional reduction beyond the initial protrusion, with mean cumulative reductions of -72.5% at the intermediate level and -78.4% at the final level. In contrast, non-supine AHI showed attenuated additional improvement despite further advancement (-16.0% from initial to intermediate, and -2.9% from intermediate to final protrusion). Correspondingly, residual apnea-hypopnea event counts decreased in both postural conditions but remained predominantly non-supine throughout titration (e-Table 4, e-Figure 5), indicating early and sustained suppression of supine-dependent events alongside a persisting non-supine residual burden.

Beyond the initial protrusion, the reduction in supine AHI exceeded the reduction observed in non-supine AHI. Accordingly, the supine-to-non-supine AHI ratio showed minimal change at the initial level (−0.1, corresponding to −3.6%) but decreased significantly from baseline at the intermediate and final titration levels (median ratios: 0.5 and 0.6; mean changes: −34.1% and −37.6%, respectively), with median values remaining below 1 (Figure 3). This divergence in response patterns was reflected in the response-rate curves across prespecified relative-change thresholds (Figure 4).

In an exploratory post-hoc analysis, we examined whether MAD titration effects on principal outcomes differed between female and male patients. Sex-specific conditioned average marginal effects were estimated from regression models incorporating a sex-by-MAD level interaction. Overall, the direction and magnitude of absolute changes in supine and non-supine AHI were similar in male and female patients, indicating no meaningful heterogeneity by sex (e-Table 5).

DISCUSSION

In this real-life OSA cohort studied under naturalistic home-sleep conditions, the main findings indicate that MAD therapy produced early and substantial improvements in AHI in both supine and non-supine positions. However, as titration progressed, a posture-specific, dose-dependent divergence emerged: supine AHI showed additional reduction beyond the initial protrusion, whereas the non-supine response attenuated after the initial protrusion and

showed little additional change thereafter. Notably, these effects were independent of changes in supine sleep time.

Prior experimental data have suggested a dose-dependent effect of mandibular advancement on UA collapsibility in OSA [27,28], and a clinical dose-response relationship has recently been reported for overall AHI [12]. However, to our knowledge, this study is the first to clinically characterize the dose-dependent patterns of MAD therapy on position-specific OSA, while clearly separating the observed improvements in residual respiratory event rate from random fluctuations in supine sleep time driven by postural behavior.

A key strength of this study is the implementation of a standardized MAD titration protocol with a uniform initial protrusion (60%), predefined, and clinically driven adjustment criteria, and multiple assessment points scheduled at relatively consistent intervals across participants. Clinical relevance is further enhanced by home-based measurements under natural sleep conditions, enabled by a compact sensor with AI-supported analysis, thereby minimizing measurement bias related to laboratory testing and observer-dependent scoring variability.

Beyond capturing detailed response trajectories across incremental MAD levels, our multiple-measurement approach mitigates major limitations of simple pre–post designs in prior MAD studies, including susceptibility to regression to the mean, night-to-night postural variability, and titration-related time-varying confounding. Our longitudinal framework also supports a more refined mechanistic interpretation of MAD-position interactions and posture-dependent UA collapsibility, yielding clinically actionable patterns rather than simple pre-post contrast.

This study has several limitations that should be acknowledged when interpreting the causal inference and clinical generalizability of the findings. First, the lack of a control or sham comparator may limit definitive causal attribution of the observed improvements to MAD alone, as regression to the mean, natural history, expectancy effects, and other contextual influences cannot be fully excluded despite the repeated-measures design and IPTW adjustment. Second, body weight and neck circumference were not reassessed during follow-up. Although major anthropometric changes were considered unlikely over the relatively short titration period in the absence of adjunctive weight-loss interventions, the lack of repeated

measurements may have limited our ability to account for these factors as potential time-varying confounders.

Additionally, because our findings were derived using a specific MAD design, they may not fully generalize to other appliances with different mechanical characteristics. Second, each MAD level was assessed only once, which may reduce the ability to separate true treatment effects from inter-night variability and to assess response stability at a given protrusion level.

Our cohort is comparable to previous oral appliance studies [5,6,29,30] in terms of demographic profile: a typical middle-aged, male-predominant population with moderate OSA. By intentionally including a mixed sample with both POSA and non-POSA phenotypes, the POSA prevalence in our study (38.5%) is lower than in POSA-enriched cohorts [5,6] (between 27 to 67.5%, depending on the definition applied). However, this approach is essential to achieve a balanced estimate of MAD effects across both supine and non-supine conditions, reducing the risk of overestimating supine-driven benefit in enriched POSA samples, and enhancing the external validity and clinical relevance of our findings for routine oral appliance prescribing in general OSA populations. We adopted the Cartwright definition [19] as it is the most widely used definition of POSA in clinical research and aligns best with our longitudinal design, which focuses primarily on respiratory event rates.

Our initial protrusion of 60% of MPR is consistent with prior POSA-specific protocols [30,31], and the intermediate advancement closely matches the 68% effective target reported using a remotely controlled mandibular titration approach, supporting its clinical relevance [32]. The therapeutic position achieved in our protocol is also comparable to the 75% maximal protrusion level reported in long-term comparative trials [30,33], which preserves efficacy while reducing adverse effects.

Our findings show early and significant responses in both supine and non-supine AHI at the starting point, which is consistent with prior observations of overall AHI [34]. However, early treatment response is not routinely reported in most previous studies [6,29,31], precluding direct cross-study comparison.

At the endpoint, the absolute reduction in supine AHI observed in our cohort falls within the range across four similar studies [5,6,29,31] (−20 to −36 events/h); however, cumulative outcomes may be influenced by heterogeneities in baseline severity and titration

protocols. Our observed relative effect on supine AHI (−78%) closely matches the post-treatment outcomes reported by Lee *et al.* (2012) [29] and Fransson *et al.* (2022) [5], but appears more favorable than the relative effects described by Dieltjens *et al.* (2014) [6] and Chung *et al.* (2010) [31]. Notably, because our cohort included a mixture of positional and non-positional phenotypes, we observed substantial improvements in both supine and non-supine AHI, differing from POSA-enriched cohorts where non-supine AHI often shows only modest relative reductions (32-49%), likely constrained by a floor-effect due to already low baseline non-supine AHI. The residual prevalence of POSA in our cohort declined to 18.3%, closely matching the residual POSA rates reported by Dieltjens *et al.* (2014) [6]. Taken together, these data suggest that MAD is effective for both supine and non-supine AHI; however, each appears to require a different degree of protrusion and has its own response limit.

Preferential and dose-responsive reductions in supine AHI with incremental mandibular advancement may be explained by posture-dependent UA mechanics. In the supine position, gravitational posterior tissue loading and reduced lung volume shift the pharynx toward a more collapsible operating point, increasing obstruction risk [3]. MAD counteracts this vulnerability by anteriorly displacing the mandible and tongue-hyoid complex, enlarging and stiffening the pharyngeal lumen, and lowering collapsibility [27,35]. Beyond structural effects, protrusion likely modifies the interaction between ventilatory control and airway mechanics, with dose-dependent reductions in collapsibility threshold and UA cross-sectional area [27,36]. By improving mechanical stability, MAD also reduces the need for compensatory dilator recruitment [37]. Within this framework, respiratory-phasic MJM can be interpreted as a respiratory drive-dependent marker of neuromuscular compensation, reflecting reflex UA dilator activation in response to increased airway load [38]. As effective titration reduces collapsing pressure, particularly in the supine posture where gravitational load is greatest, the compensatory drive and associated MJMs decline accordingly.

In contrast, the baseline collapsing load is lower in non-supine posture; once the anatomical component is mitigated, residual events are more influenced by non-anatomical traits (loop gain, arousal threshold, and limited dilator responsiveness) that MAD does not robustly modify [35, 39-41], explaining the limited additional benefit on non-supine AHI.

From a clinical perspective, these findings suggest that the effectiveness of MAD therapy should be assessed under naturalistic sleep conditions at home, with explicit attention

to position-dependent OSA burden. In this context, integrating MJM-based home monitoring into the therapy workflow offers a practical way to achieve repeatable, posture-stratified evaluation of residual AHI across multiple nights. This continuous feedback may support earlier phenotype confirmation, improved characterization of individual response patterns, and more adaptive clinical decision-making aligned with the dose-response trajectories observed during titration. In the absence of validated minimal clinically important difference (MCID) thresholds for positional AHI outcomes, a response pattern-centered approach may provide a more flexible framework for interpreting individual responses during MAD titration. For example, progressive improvement in AHI may support continued advancement until a comfort-limited position or a treatment target is reached. Conversely, little additional improvement may suggest that the therapeutic position has been reached; if the overall response remains suboptimal, it points toward the need for adjunctive strategies such as positional therapy, weight management, or nasal optimization. The distinct response patterns observed for supine and non-supine AHI also suggest that combining MAD with positional therapy could reduce the degree of protrusion required to achieve AHI normalization, supporting a more individualized treatment approach. An unstable response trajectory may suggest the influence of inter-night variability, adherence issues or behavioral factors. Finally, the absence of response or a declining efficacy trajectory may warrant deeper investigation into mechanisms of treatment failure or consideration of alternative treatments. Beyond respiratory indices, optimization of MAD therapy may also benefit coexisting sleep bruxism, as MAD treatment has been reported to reduce the frequency of sleep bruxism episodes in such patients [42].

This study also provides a foundation for future research to develop and refine MJM-guided titration strategies by determining key implementation parameters, including the monitoring window, the required number of nights, actionable thresholds, and response pattern-driven decision rules.

CONCLUSION

In conclusion, this study provides clinical evidence for a dose-response relationship between mandibular advancement and positional OSA, further clarifying the dynamic interplay between incremental mandibular advancement and posture-dependent UA collapsibility. This interaction is reflected by divergent response trajectories between supine and non-supine AHI across advancement levels. These findings underscore the value of

continuous home-based monitoring of position-specific AHI under naturalistic sleep conditions during MAD titration and support the integration of MJM-based monitoring into the conventional MAD therapy workflow. Such an approach is expected to shorten the time to optimal therapeutic mandibular position, enable earlier identification of treatment success or failure, and optimize MAD titration efficiency, ultimately contributing to better patient clinical outcomes.

References

1. Ramar K, Dort LC, Katz SG, Lettieri CJ, Harrod CG, Thomas SM, Chervin RD. Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: an update for 2015. J Clin Sleep Med 2015;11(7):773–827.

2. Phillips C, Grunstein R, Darendeliler A, et al. Health outcomes of continuous positive airway pressure versus oral appliance treatment for obstructive sleep apnea: a randomized controlled trial. Am J Respir Crit Care Med. 2013;187(8):879-87. doi: 10.1164/rccm.201212-2223OC.

3. Joosten SA, O'Driscoll DM, Berger PJ, Hamilton GS. Supine position related obstructive sleep apnea in adults: pathogenesis and treatment. Sleep Med Rev. 2014;18(1):7-17. doi: 10.1016/j.smrv.2013.01.005.

4. Milano F, Mutinelli S, Sutherland K, Milioli G, Scaramuzzino G, Cortesi AB, Siciliani G, Lombardo L, Cistulli PA. Influence of vertical mouth opening on oral appliance treatment outcome in positional obstructive sleep apnea. J Dent Sleep Med. 2018;5(1):17-23. doi:10.15331/jdsm.6918.

5. Fransson AMC, Isacsson G, Nohlert E. The outcome of oral appliance therapy on position-dependent obstructive sleep apnea: A multicenter randomized controlled trial. Am J Orthod Dentofacial Orthop. 2022;162(3):386-393. doi: 10.1016/j.ajodo.2021.04.029

6. Dieltjens M, Braem MJ, Van de Heyning PH, Wouters K, Vanderveken OM. Prevalence and Clinical Significance of Supine-Dependent Obstructive Sleep Apnea in Patients Using Oral Appliance Therapy. J Clin Sleep Med. 2014;10(9):959–964. doi: 10.5664/jcsm.4024

7. Buyse B, Nguyen PAH, Leemans J, Verhaeghe V, Peters M, et al. Short-term positive effects of a mandibular advancement device in a selected phenotype of patients with moderate obstructive sleep apnea: a prospective study.J Clin Sleep Med. 2023;19(1):5-16.doi: 10.5664/jcsm.10232.

8. Yo WS, Joosten SA, Wimaleswaran H, Mansfield D, Thomson L, et al. Body position during laboratory and home polysomnography compared to habitual sleeping position at home. J Clin Sleep Med. 2022;18(9):2103–2111. doi: 10.5664/jcsm.9990

9. Metersky ML, Castriotta RJ. The effect of polysomnography on sleep position: possible implications on the diagnosis of positional obstructive sleep apnea. Respiration. 1996;63(5):283-7. doi: 10.1159/000196561.

10. Razjouyan J, Lee H, Parthasarathy S, Mohler J, Sharafkhaneh A, Najafi B. Improving Sleep Quality Assessment Using Wearable Sensors by Including Information From Postural/Sleep Position Changes and Body Acceleration: A Comparison of Chest-Worn Sensors, Wrist Actigraphy, and Polysomnography. J Clin Sleep Med. 2017;13(11):1301–1310. doi: 10.5664/jcsm.6802

11. Pépin JL, Cistulli PA, Crespeigne E, et al. Mandibular Jaw Movement Automated Analysis for Oral Appliance Monitoring in Obstructive Sleep Apnea: A Prospective Cohort Study. Ann Am Thorac Soc. 2024 May;21(5):814-822. doi: 10.1513/AnnalsATS.202312-1077OC.

12. Pépin JL, Martinot JB, Le-Dong NN, et al. Exploring the Dose-Response Relationship Between Mandibular Protrusion and Respiratory Effort Burden in Oral Appliance Therapy for OSA. Ann Am Thorac Soc. 2025. Online ahead of print. doi: 10.1513/AnnalsATS.202408-889OC.

13. Malhotra A, Martinot JB, Pépin JL. Insights on mandibular jaw movements during polysomnography in obstructive sleep apnea. J Clin Sleep Med. 2024;20(1):151-163. doi: 10.5664/jcsm.10830.

14. U.S. Food and Drug Administration. K250874 - 510(k) Premarket Notification [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2026 Mar 2 [cited 2026 Mar 8]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K250874

15. Berry RB, Brooks R, Gamaldo C, Harding SM, Lloyd RM, Quan SF, Troester MT, Vaughn BV. AASM Scoring Manual Updates for 2017 (Version 2.4). J Clin Sleep Med 2017;13:665-666.

16. Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, Marcus CL, Mehra R, Parthasarathy S, Quan SF, Redline S, Strohl KP, Davidson Ward SL, Tangredi MM. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med 2012;8:597-619.

17. American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien (IL): American Academy of Sleep Medicine; 2014.

18. R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2024. Available from: https://www.R-project.org

19. Cartwright R.D. Effect of sleep position on sleep apnea severity. Sleep. 1984;7:110–114. doi: 10.1093/sleep/7.2.110

20. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000 Sep;11(5):550-60. doi:10.1097/00001648-200009000-00011.

21. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008 Sep 15;168(6):656-64. doi:10.1093/aje/kwn164.

22. Imai K, van Dyk DA. Causal inference with general treatment regimes: generalizing the propensity score. J Am Stat Assoc. 2004 Sep;99(467):854-866.

23. Hirano K, Imbens GW. The propensity score with continuous treatments. In: Gelman A, Meng XL, editors. Applied Bayesian Modeling and Causal Inference from Incomplete-Data Perspectives. Chichester (UK): Wiley; 2004. p. 73-84. doi:10.1002/0470090456.ch7.

24. Imbens GW. The role of the propensity score in estimating dose-response functions. Biometrika. 2000 Sep;87(3):706-710. doi:10.1093/biomet/87.3.706.

25. Mikis D. Stasinopoulos, Robert A. Rigby, Gilllian Z. Heller, Vlasios Voudouris, Fernanda De Bastiani. Flexible Regression and Smoothing: Using GAMLSS in R. Chapman & Hall/CRC, Boca Raton, 2017. ISBN 978-1-138-19790-9

26. Arel-Bundock V, Greifer N, Heiss A. How to Interpret Statistical Models Using marginaleffects for R and Python. Journal of Statistical Software 2024 ;111(9) : 1-32. doi:10.18637/jss.v111.i09 https://doi.org/10.18637/jss.v111.i09.

27. Bamagoos AA, Cistulli PA, Sutherland K, Ngiam J, Burke PG, et al. Dose-dependent effects of mandibular advancement on upper airway collapsibility and muscle function in obstructive sleep apnea. Sleep. 2019;42(6):zsz049. doi: 10.1093/sleep/zsz049.

28. Ma Y, Yu M, Gao X. The effect of gradually increased mandibular advancement on the efficacy of an oral appliance in the treatment of obstructive sleep apnea. J Clin Sleep Med. 2020 Aug 15;16(8):1369–1376. doi: 10.5664/jcsm.8556

29. Lee CH, Jung HJ, Lee WH, Rhee CS, Yun PY, Kim JW. The Effect of Positional Dependency on Outcomes of Treatment With a Mandibular Advancement Device. Arch Otolaryngol Head Neck Surg. 2012;138;(5):479-483. doi:10.1001/archoto.2012.452

30. de Ruiter MHT, Aarab G, de Vries N, Lobbezoo F, de Lange J. A stepwise titration protocol for oral appliance therapy in positional obstructive sleep apnea patients: proof of concept. Randomized Controlled Trial Sleep Breath. 2020;24(3):1229-1236. doi: 10.1007/s11325-020-02045-w.

31. Chung JW, Enciso R, Levendowski DJ, Morgan TD, Westbrook PR, Clark GT. Treatment outcomes of mandibular advancement devices in positional and nonpositional OSA patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(5):724-31. doi: 10.1016/j.tripleo.2009.11.031.

32. Remmers J, Charkhandeh S, Grosse J, Topor Z, Brant R, et al. Remotely Controlled Mandibular Protrusion during Sleep Predicts Therapeutic Success with Oral Appliances in Patients with Obstructive Sleep Apnea. Sleep. 2013;36(10):1517–1525. doi: 10.5665/sleep.3048

33. Tegelberg A, Walker-Engström ML, Vestling O, Wilhelmsson B. Two different degrees of mandibular advancement with a dental appliance in treatment of patients with mild to moderate obstructive sleep apnea. Acta Odontol Scand. 2003;61(6):356-62. doi: 10.1080/00016350310007130

34. Anitua E, Durán-Cantolla J, Almeida GZ, Alkhraisat MH. Minimizing the mandibular advancement in an oral appliance for the treatment of obstructive sleep apnea. Sleep Med 2017;34:226-231.

35. Edwards BA, Andara C, Landry S, Sands SA, Joosten SA, et al. Upper-Airway Collapsibility and Loop Gain Predict the Response to Oral Appliance Therapy in Patients with Obstructive Sleep Apnea. Am J Respir Crit Care Med. 2016;194(11):1413–1422. doi: 10.1164/rccm.201601-0099OC

36. Garcia GJM, Wolf J, Campbell DA, Bailey RS, et al. Mandibular advancement reduces pharyngeal collapsibility by enlarging the airway rather than affecting velopharyngeal compliance. Physiol Rep. 2023;11(3):e15558. doi: 10.14814/phy2.15558.

37. Almeida FR, Tsuiki S, Hattori Y, Takei Y, Inoue Y, Lowe AA. Dose-dependent effects of mandibular protrusion on genioglossus activity in sleep apnoea. Eur Respir J. 2011 Jan;37(1):209-12. doi: 10.1183/09031936.00194809.

38. Martinot JB, Tong B, Le-Dong NN, Pépin JL, Cistulli PA. Expert Rev Med Devices. 2026;23(2):141-157. doi: 10.1080/17434440.2026.2615782. Emerging monitoring techniques in oral appliance therapy for sleep apnea: a narrative review with a focus on mandibular jaw movement analysis.

39. Owens RL, Edwards BA, Eckert DJ, Jordan AS, Sands SA, et al. An Integrative Model of Physiological Traits Can be Used to Predict Obstructive Sleep Apnea and Response to Non Positive Airway Pressure Therapy. Sleep. 2015;38(6):961–970. doi: 10.5665/sleep.4750

40. Eckert DJ, White DP, Jordan AS, Malhotra A, Wellman A. Defining Phenotypic Causes of Obstructive Sleep Apnea. Identification of Novel Therapeutic Targets. Am J Respir Crit Care Med. 2013;188(8):996–1004. doi: 10.1164/rccm.201303-0448OC

41. Op de Beeck S, Dieltjens M, Azarbarzin A, Willemen M, Verbraecken J, et al.Mandibular Advancement Device Treatment Efficacy Is Associated with Polysomnographic Endotypes. Ann Am Thorac Soc. 2021;18(3):511–518. doi: 10.1513/AnnalsATS.202003-220OC

42. Martynowicz H, Wieczorek T, Macek P, Wojakowska A, Poręba R, Gac P, et al. The effect of continuous positive airway pressure and mandibular advancement device on sleep bruxism intensity in obstructive sleep apnea patients. Chron Respir Dis. 2022;19:14799731211052301. doi:10.1177/14799731211052301.

Data availability

Data is not publicly available. However, de-identified data may be obtained from the corresponding author upon reasonable request, subject to a data-sharing agreement and approval by the relevant ethics committee.

TABLES

Table 1: Study population characteristics at baseline

Parameters (unit/scale)	Median [IQR] or Frequency (%) (n=96)
Age (year)	46.81 [39.75 – 52.65]
Male sex (n)	72 (75.0 %)
BMI (kg/m^2)	27.17 [25.37 – 29.05]
Neck circumference (cm)	40.00 [37.75 – 42.00]
Maximal protrusion range (mm)	13.0 [11.0 – 14.0]
ESS score (0-24)	10.0 [8.0 – 14.0]
Diagnostic PSG indices	
TST (hours)	7.07 [6.09 – 7.64]
SEff (% recording time)	68.41 [57.27 – 77.40]
AHI (n/h)	24.16 [18.61 – 34.62]
ArI (n/h)	27.62 [21.55 – 37.06]
ODI (n/h)	15.85 [6.79 – 27.48]
OSA severity	
Mild (AHI 5 to <15/h)	13 (13.54 %)
Moderate (AHI 15 to <30/h)	49 (51.04 %)
Severe (AHI ≥30/h)	34 (35.42%)
Position-specific indices *	
Supine sleep time proportion (%)	19.09 [6.81 – 37.90]
nAH supine (n)	33.5 [0.0 – 69.5]
nAH non-supine (n)	84.0 [44.0 – 125.75]
Supine AHI (n/h)	20.29 [0.00 – 36.66]
Non-supine AHI (n/h)	17.43 [9.81 – 23.94]
Supine AH proportion (%)	30.29 [0.00 – 58.62]
Supine/non-supine AHI ratio	1.47 [0.00 – 2.58]
POSA prevalence	37 (38.54 %)

Note: Numeric variables are presented as median [interquartile range]; categorical variables are presented as frequency (%). Abbreviations: AHI = apnea–hypopnea index; ArI = arousal index; BMI = body mass index; ESS = Epworth Sleepiness Scale; nAH = apnea/hypopnea event count; ODI = oxygen desaturation index; POSA = positional obstructive sleep apnea, defined as supine/non-supine AHI ratio ≥ 2; PSG = polysomnography ; SEff = sleep efficiency; TST = total sleep time. *Position-specific indices were measured using mandibular jaw movement (MJM)-based analysis performed at home prior to MAD treatment. Supine and non-supine positions were determined by continuous tri-axial accelerometer monitoring.

Table 2: Average treatment effects of MAD on position-specific apnea-hypopnea indices

Outcomes	Contrast	Absolute change			Relative change (% of prior level)		
		Estimated	95% CI	p-value #	Estimated	95% CI	p-value #
Supine AHI *(n/h)*	IP – Base	-22.78	-28.46 ; -17.11	<0.0001	-60.06 %	-67.92 ; -52.21	<0.0001
	Intermediate – Base	-27.49	-32.86 ; -22.11	<0.0001	-72.47 %	-77.76 ; -67.17	<0.0001
	Final – Base	-29.75	-35.19 ; -24.31	<0.0001	-78.44 %	-82.68 ; -74.19	<0.0001
	Intermediate – IP	-4.70	-7.34 ; -2.07	0.0006	-31.06 %	-45.10 ; -17.01	<0.0001
	Final – IP	-6.97	-9.47 ; -4.47	<0.0001	-46.00 %	-57.04 ; -34.96	<0.0001
	Final – Intermediate	-2.26	-4.19 ; -0.34	0.0211 (NS)	-21.68 %	-37.61 ; -5.74	0.0077 (NS)
Non-supine AHI *(n/h)*	IP – Base	-10.99	-13.07 ; -8.91	<0.0001	-55.01 %	-61.11 ; -48.91	<0.0001
	Intermediate – Base	-12.43	-14.43 ; -10.42	<0.0001	-62.19 %	-67.22 ; -57.16	<0.0001
	Final – Base	-12.65	-14.66 ; -10.63	<0.0001	-63.29 %	-68.24 ; -58.34	<0.0001
	Intermediate – IP	-1.43	-2.57 ; -0.30	0.0162 (NS)	-15.96 %	-27.47 ; -4.45	0.0079 (NS)
	Final – IP	-1.65	-2.78 ; -0.53	0.006 (NS)	-18.40 %	-29.60 ; -7.20	0.0019
	Final – Intermediate	-0.22	-1.23 ; 0.80	0.6722 (NS)	-2.90 %	-16.14 ; 10.34	0.6675 (NS)
Supine AH proportion *(% of total AH events)*	IP – Base	-10.71	-16.60 ; -4.81	0.0007	-23.92 %	-35.63 ; -12.21	0.0001
	Intermediate – Base	-11.77	-17.48 ; -6.06	0.0002	-26.27 %	-37.37 ; -15.18	<0.0001
	Final – Base	-15.48	-21.27 ; -9.70	<0.0001	-34.43 %	-45.23 ; -23.64	<0.0001
	Intermediate – IP	-1.07	-6.92 ; 4.79	0.7209 (NS)	-3.12 %	-19.96 ; 13.71	0.716
	Final – IP	-4.78	-10.70 ; 1.14	0.114	-13.92 %	-29.93 ; 2.10	0.088
	Final – Intermediate	-3.71	-9.44 ; 2.02	0.204	-11.15 %	-27.44 ; 5.14	0.180
Supine/non-supine AHI ratio	IP – Base	-0.09	-0.66 ; 0.47	0.7466 (NS)	-3.55 %	-24.72 ; 17.63	0.7426 (NS)
	Intermediate – Base	-0.89	-1.36 ; -0.42	0.0005	-34.06 %	-48.12 ; -20.00	<0.0001
	Final – Base	-0.99	-1.45 ; -0.52	0.0002	-37.63 %	-51.15 ; -24.11	<0.0001
	Intermediate – IP	-0.80	-1.29 ; -0.30	0.0016	-31.64 %	-47.13 ; -16.15	<0.0001
	Final – IP	-0.89	-1.38 ; -0.40	0.0004	-35.33 %	-50.15 ; -20.51	<0.0001
	Final – Intermediate	-0.09	-0.47 ; 0.28	0.6256 (NS)	-5.40 %	-26.52 ; 15.71	0.7391 (NS)
Supine sleep time proportion (%TST)	IP – Base	-4.34	-7.54 ; -1.15	0.0466 (NS)	-19.87 %	-33.04 ; -6.70	0.0187 (NS)
	Intermediate – Base	-1.30	-4.53 ; 1.93	0.5164 (NS)	-6.02 %	-20.52 ; 8.48	0.4992 (NS)
	Final – Base	-3.32	-6.52 ; -0.13	0.1249 (NS)	-15.26 %	-28.80 ; -1.71	0.0818 (NS)

	Intermediate – IP	3.04	-0.17 ; 6.26	0.1267 (NS)	17.39 %	-2.61 ; 37.40	0.1767 (NS)
	Final – IP	1.02	-2.16 ; 4.20	0.5283 (NS)	5.79 %	-12.75 ; 24.33	0.5404 (NS)
	Final – Intermediate	-2.02	-5.23 ; 1.19	0.3259 (NS)	-9.85 %	-24.69 ; 5.00	0.2905 (NS)

Note: The table reports the average absolute and relative changes in five targeted outcomes at a given MAD protrusion level compared with a preceding level during titration (IP = initial protrusion level). Estimates were obtained from regression models using the appropriate probability distributions law for each outcome (zero-adjusted gamma for supine/non-supine AHI and the positional AHI ratio; beta distribution for the proportion of supine AHI and supine sleep time proportion). For each pair of comparison, results are presented as average marginal effects with 95% confidence intervals. All models incorporated inverse probability weighting (IPW) to adjust for the effects of age, sex, BMI, MPR, and the time-varying confounding attributable to residual ESS, snoring, and adverse effects at each MAD protrusion level.

#: p values were derived from two-sided Wald tests assessing the null hypothesis of no change, with Benjamini–Hochberg adjustment for multiple comparisons and a significance threshold of 0.005.

Abbreviations: AH = apneas and hypopneas; AHI = apnea–hypopnea index; TST = total sleep time; NS = not significant.

FIGURES TITLE AND LEGEND

Figure 1: Study flowchart

Legend: MAD = mandibular advancement device; IP = initial protrusion level; T1 = intermediate level; T2 = final level; OSA = obstructive sleep apnea.

Figure 2: Changes in position-specific apnea-hypopnea indices during MAD titration

Legend: Upper panel: Two plots illustrate the changes in the distribution of supine AHI (a) and non-supine AHI (b) on the y-axis across four incremental levels of MAD protrusion on the x-axis. Each plot includes two layers: a background layer showing kernel density curves for the distribution of the outcome at each time point, and a foreground layer showing individual trajectories as connected points, with each dot representing an individual value. Larger dots indicate the median value at each time point, and the dashed line connecting them represents the population-level trend. Lower panel: Divergence between the supine and non-supine trajectories of dose-dependent AHI reduction relative to baseline. Supine is shown in red (lower curve) and non-supine in blue (upper curve). The x-axis indicates the three mandibular advancement levels; the y-axis shows the cumulative reduction for each outcome (as % of baseline). Circles and error bars indicate the mean effect and its 95% confidence interval, respectively.

Figure 3: Changes in supine versus non-supine AHI ratio and proportion of non-supine residual apnea-hypopnea events

Legend: The figure illustrates changes in the distribution of: (a) the ratio of supine AHI/non supine AHI, and (b): the proportion of residual apnea and hypopnea events in non-supine position, across four time points during the MAD titration process (x-axis), with the same graphical structure as in Figure 2.

Figure 4: Response rate across different relative change thresholds



Legend: The curves show the proportion of patients (y-axis) meeting the response criterion at each prespecified relative-change threshold (x-axis) at 3 protrusion levels, for supine AHI (left) and non-supine AHI (right). For each threshold, responders were defined as patients with a relative change from baseline greater than the threshold.



(a)

(b)

AHI in supine position (n/h)

AHI in non supine position (n/h)

100
90
80
70
60
50
40
30
20
10
0

Baseline
Initial
Intermediate
Final

(c)

Relative reduction in AHI (% of baseline)

−45
−50
−55
−60
−65
−70
−75
−80
−85

non-supine
supine

Initial
Intermediate
Final

(a)



(b)





Dose-response Relationship between Mandibular Advancement and OSA Burden: Dissociated Effects on Supine and Non-Supine AHI

HIGHLIGHTS

- MAD titration was associated with dose-dependent changes in position-specific OSA burden
- Early and meaningful improvement was observed for both supine and non-supine AHI
- Data revealed distinct trajectories of supine versus non-supine AHI responses
- MAD titration did not produce a clinically meaningful change in supine sleep exposure

Declaration of Conflict of Interests Statement

For the manuscript *'Dose-response Relationship between Mandibular Advancement and OSA Burden: Dissociated Effects on Supine and Non-Supine AHI'*

Conflicts of interest and Funding

JBM is a scientific advisor to Sunrise and has been an investigator in pharmaceutical trials for Jazz Pharmaceuticals and Takeda.

NNLD is an employee of Sunrise.

CC has no financial disclosure

DC has no financial disclosure.

FA has no financial disclosure.

PAC has an appointment to an endowed academic Chair at the University of Sydney that was created from ResMed funding. He receives no personal fees, and this relationship is managed by an Oversight Committee of the University. He has received research support from ResMed, SomnoMed, Nox Medical, and MyCardio. He is a consultant/adviser to ResMed, SomnoMed, Sunrise, and Eli Lilly.

JLP is supported by the French National Research Agency (ANR) in the framework of the "FRANCE 2030" program, the "e-health and integrated care" chair of Grenoble Alpes University Foundation, and the "Sleep Health-AI chair" within the "MIAI Cluster" for artificial intelligence (ANR-23-IACL-0006). He also reports income related to medical education from ResMed, Sefam, Zoll-Respicardia, Eli Lilly, Idorsia, Pharmanovia, Biosency, and Bioprojet.

Declaration of interests

☐ The authors declare that they have no competing financial interests or personal relationships that could be perceived to have influenced the work reported in this paper.

☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

JBM is a scientific advisor to Sunrise and has been an investigator in pharmaceutical trials for Jazz Pharmaceuticals and Takeda.

NNLD is an employee of Sunrise.

CC has no financial disclosure

DC has no financial disclosure.

FA has no financial disclosure.

PAC has an appointment to an endowed academic Chair at the University of Sydney that was created from ResMed funding. He receives no personal fees, and this relationship is managed by an Oversight Committee of the University. He has received research support from ResMed, SomnoMed, Nox Medical, and MyCardio. He is a consultant/adviser to ResMed, SomnoMed, Sunrise, and Eli Lilly.

JLP is supported by the French National Research Agency (ANR) in the framework of the "FRANCE 2030" program, the "e-health and integrated care" chair of Grenoble Alpes University Foundation, and the "Sleep Health-AI chair" within the "MIAI Cluster" for artificial intelligence (ANR-23-IACL-0006). He also reports income related to medical education from ResMed, Sefam, Zoll-Respicardia, Eli Lilly, Idorsia, Pharmanovia, Biosency, and Bioprojet.